Thymosin Alpha 1 Dosage: A Comprehensive Research Guide

Thymosin alpha 1 is a synthetic acetylated polypeptide derived from the thymus gland that has garnered significant research interest for its immunomodulatory properties . Known commercially as thymalfasin (Zadaxin), this peptide primarily enhances cellular immunity with a well-established safety profile across multiple clinical applications . For researchers and clinicians seeking thymosin alpha 1 dosage information, this guide synthesizes data from clinical trials, approved protocols, and emerging research.

Standard Thymosin Alpha 1 Dosage Protocols

The most widely established thymosin alpha 1 dosage follows a consistent pattern across approved indications. The standard unit dose is 1.6 mg per injection, administered subcutaneously .

Chronic Hepatitis B Protocol Thymosin Alpha 1 Dosage 

For chronic hepatitis B, the recommended thymosin alpha 1 dosage regimen is:

• Dose: 1.6 mg per injection

• Frequency: Twice weekly

• Interval: 3-4 days between doses

• Duration: 6 months (total of 52 injections)

• Administration: Subcutaneous injection 

Clinical trials have demonstrated that thymosin alpha 1 monotherapy at 1.6 mg achieves comparable efficacy to 0.8 mg dosing for various hepatitis B markers, with advanced fibrosis patients showing significantly better outcomes with the 1.6 mg dose at 24 weeks .

Vaccine Immune Response Enhancement Thymosin Alpha 1 Dosage 

When used as an immunoadjuvant for vaccine response in immunocompromised patients:

• Dose: 1.6 mg per injection

• Frequency: Twice weekly

• Interval: 3-4 days between doses

• Duration: 4 weeks (total of 8 injections)

• Administration: First dose immediately following vaccine administration 

This thymosin alpha 1 dosage protocol is indicated for elderly patients, those on chronic hemodialysis, and other immunocompromised populations to enhance responses to influenza or hepatitis B vaccines .

Loading Dose Protocols in Cancer Immunotherapy Research

Recent clinical trials have explored personalized thymosin alpha 1 dosage approaches in combination with immunoradiotherapy regimens for advanced solid tumors. The PRaG 5.0 study (NCT05790447) introduced a stratified dosing strategy :

For Patients with Low Baseline T-Lymphocyte Counts

• Loading Phase: 7-day loading dose protocol

• Maintenance Phase: 1.6 mg thrice weekly following loading

For Patients with Normal T-Lymphocyte Counts

• Maintenance Only: 1.6 mg thrice weekly

Among 39 treated patients in the PRaG 5.0 study, 30 required the loading dose protocol . Immune analysis revealed significant increases in CD8+ T cells, NK cells, and CD4+TEM cells following the thymosin alpha 1 loading dose, with notable decreases in Tregs .

Specialized Research Protocols Thymosin Alpha 1 Dosage 

Depression in Common Variable Immunodeficiency

A proof-of-concept study investigating thymosin alpha 1 for depressive symptoms in CVID patients utilized a unique dosage schedule :

• Week 1: 1.6 mg daily subcutaneously

• Weeks 2-8: 1.6 mg twice weekly

• Duration: 8 weeks total

All five treated patients showed a 52% average decrease in Hamilton Depression Rating Scale scores, with immune improvements including increased naïve/memory T cell ratios .

Sepsis Research

A Phase III trial for sepsis patients utilized a more intensive thymosin alpha 1 dosage:

• Dose: 1.6 mg per injection

• Frequency: Twice daily (BID)

• Duration: 7 consecutive days

• Administration: Subcutaneous 

Preparation and Administration Thymosin Alpha 1 Dosage 

Thymosin alpha 1 is supplied as a lyophilized powder in vials containing 1.6 mg of the active peptide . The standard preparation protocol requires:

1. Reconstitution with 1.0 mL of sterile water for injection

2. Dissolution immediately prior to use

3. Subcutaneous administration

4. Intramuscular injection is also noted as acceptable in some protocols 

The peptide solution should be used promptly after reconstitution to maintain stability.

Important Research Considerations Thymosin Alpha 1 Dosage 

Researchers should note that thymosin alpha 1 is classified as a non-reimbursable treatment in many healthcare systems, with off-label use common in oncology settings despite the approved indication being primarily for hepatitis B and vaccine immune enhancement . The peptide has demonstrated a favorable safety profile across studies, with no Grade 3 or above treatment-related adverse events reported in recent immunotherapy combination trials .

The efficacy of thymosin alpha 1 appears to be dose-dependent in certain contexts, with 1.6 mg showing advantages over 0.8 mg in advanced fibrosis patients, while both doses demonstrated comparable efficacy in broader hepatitis B cohorts .